NeuroTrauma Sciences appoints new executives
25 March 2021 -

NeuroTrauma Sciences LLC, a United States-based biopharmaceutical company, announced on Wednesday that it has named Judith Hedstrom as its new chief operating officer, Anthony Caggiano, MD, PhD as its new chief medical officer and head of Research & Development and David Lawrence as chief financial officer.

Hedstrom has over 25 years' experience in accelerating life science product development and growth. She has held various executive roles, including senior vice president of Corporate and Business Development, chief operating officer of Alteon Inc and vice president of Strategic Planning and Business Development for APACHE Medical Systems. She has consulted for biotechnology, pharmaceutical, medical products and diagnostic companies on various high-impact matters, and has assumed transitional executive leadership positions at several life science companies.

Dr Caggiano has over 20 years of experience in the biopharmaceutical industry. He has held the position of chief medical officer for Cognition Therapeutics, Constant Pharmaceuticals and Aeromics Inc, and as senior vice president of research and development at Acorda Therapeutics.

Lawrence has held the position of chief financial officer at NeuroTrauma Sciences. He has over two decades of experience at Acorda Therapeutics covering several financial roles including chief, business operations and principal accounting officer and chief financial Officer.